Autres langues Celltrion, Inc.

Actions

A068270

KR7068270008

Cours en clôture Korea S.E. Autres places de cotation 00:00:00 03/05/2024			Varia. 5j.	Varia. 1 janv.
189 000 ^KRW	+0,80%		+7,02%	-6,20%

17/04	Celltrion, Inc. (KOSE:A068270) annonce un rachat d'actions pour 436 047 actions.	CI
17/04	Celltrion, Inc. autorise un plan de rachat.	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Market Share of Celltrion’s Remsima Rises to 74% in Europe	24/04
MDL Panel Grants Transfer Of Aflibercept BPCIA Case	22/04
Celltrion, Inc. announces an Equity Buyback for 436,047 shares.	17/04
Celltrion, Inc. authorizes a Buyback Plan.	17/04
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on March 5, 2024.	28/03
Updates On Aflibercept BPCIA Litigation	26/03
Celltrion, Inc.'s Equity Buyback announced on March 5, 2024, has closed with 425,895 shares, representing 0.21% for KRW 78,072.21 million.	26/03
Fresenius Kabi's Actemra® Biosimilar Tyenne® (Tocilizumab-aazg) Approved In The U.S.	20/03
Celltrion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03
South Korean Shares Close Higher on Tech Gains; Celltrion Shares Add 1% on Zymfentra Launch in the US	18/03
Celltrion's Autoimmune Disease Treatment Hits US Markets	18/03
South Korean Shares Slightly Slip as Investors Seek Cues on Future Rate Direction from US Fed	06/03
Celltrion Announces 75 Billion Won Share Buyback Plan	06/03
Genentech And Partners Voluntarily Dismiss IPR Appeals Related To Genentech's ACTEMRA® (Tocilizumab)	05/03
Celltrion, Inc. announces an Equity Buyback for 425,895 shares.	05/03
Celltrion, Inc. authorizes a Buyback Plan.	05/03
PTAB Institutes Celltrion And Biocon IPRs On Regeneron Aflibercept Dosing Patent	29/02
South Korean Shares Dip on Tech, Pharma Losses; Celltrion Sheds 5% on Lackluster Q4 Earnings	29/02
Celltrion's Net Profit Nosedives 98.5% in Q4 2023 as Revenue Declines 25%	29/02
Celltrion Submits An ABLA For Actemra® (Tocilizumab) Proposed Biosimilar CT-P47	29/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Celltrion, Inc.

Actions

A068270

KR7068270008

Autres langues

Filtres